1. Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study
- Author
-
Megan Telfer, Joseph Timpone, Tondria Green, Edward P. Acosta, Jay Dwyer, Michael P. DubCrossed Dsign, Ellen S. Chan, Paul E. Sax, David Rusin, Teri Flynn, Raphael J. Landovitz, Todd T. Brown, Carl J. Fichtenbaum, Amy Sbrolla, Jolene Noel-Connor, Cara Wilson, Roula Qaqish, Daniel Reirden, Pamela Poethke, Athe M. N. Tsibris, Olga I. Mendez, Babafemi Taiwo, Jorge Santana, Shelia B. Dunaway, Ge-Youl Kim, Yolanda Smith, Tim Lane, Joseph J. Eron, James F. Rooney, Mark Hite, Vanessa Cajahuaringa, Ilene Wiggins, Cheryl Keenan, Cornelius N Van Dam, Nina Lambert, Beverly E. Sha, Mark Rodrieguez, Orlando Roman, I. Martinez, Miriam Chicurel-Bayard, Cathi Basler, Karen Coleman, Laura A. Napolitano, Robert C. Kalayjian, Bryan Baugh, Fred Nicotera, Baiba Berzins, Roberto C. Arduino, Kathy Melbourne, Tamara James, Mary Adams, Charles Walworth, Kevin Robertson, Alan L. Landay, Princy Kumar, Melody Palmore, Andrea Weiss, Heera R. Jayvant, Christine Griesmer, Igho Ofotokun, Christos J. Petropoulos, Aleshia Thomas, John A. Davis, Pablo Tebas, Amy Gonzales, Patricia Walton, Constance A. Benson, Alex Reinhart, Brenda Jackson, Rose Kim, Bartolo Santos, Ighovwerha Ofotokun, Annie Luetkemeyer, Heather J. Ribaudo, Karin L. Klingman, Jenifer Baer, Amy Dill, Felicia Williams, Michael T. Yin, Christine Hurley, Hector Bolivar, Edward Seefried, Aadia Rana, Sheryl Storey, Margaret A. Fischl, Hannah Bernath, and Aristoteles E. Villamil
- Subjects
Microbiology (medical) ,musculoskeletal diseases ,Adult ,Male ,medicine.medical_specialty ,Bone density ,Anti-HIV Agents ,Population ,HIV Infections ,Emtricitabine ,Gastroenterology ,Maraviroc ,chemistry.chemical_compound ,Bone Density ,Cyclohexanes ,Internal medicine ,medicine ,Humans ,education ,Pelvic Bones ,Tenofovir ,Darunavir ,education.field_of_study ,business.industry ,virus diseases ,Middle Aged ,Triazoles ,medicine.disease ,Surgery ,Osteopenia ,Infectious Diseases ,chemistry ,HIV/AIDS ,Ritonavir ,Female ,business ,Viral load ,medicine.drug - Abstract
Background. There is a need to prevent or minimize bone loss associated with antiretroviral treatment (ART) initiation. We compared maraviroc (MVC)- to tenofovir disoproxil fumarate (TDF)–containing ART. Methods. This was a double-blind, placebo-controlled trial. ART-naive subjects with human immunodeficiency virus type 1 RNA load (viral load [VL]) >1000 copies/mL and R5 tropism were randomized to MVC 150 mg or TDF 300 mg once daily (1:1), stratified by VL
- Published
- 2015